Literature DB >> 26262920

A Challenging Cutaneous T-Cell Lymphoma.

Aida Khadhar1, Ines Chelly, Alia Zehani, Noureddine Litaiem, Ines Zaraa, Haifa Azouz, Khadija Bellil, Antoine de Mascarel, Slim Haouet, Nidhameddine Kchir.   

Abstract

Cutaneous peripheral T-cell lymphomas not otherwise specified (CPTL-NOS) are rare neoplasms accounting for just 2% of cutaneous peripheral T-cell lymphomas (CPTL). Only very few case series have been reported. They represent a phenotypically and prognostically heterogenous group of CPTL that do not fit into any of CPTL well-defined subtypes. The authors report a case of a 64-year-old man with simultaneous plaque-like lesions and disseminated nodules growing rapidly on the face, trunk, and extremities over a 6-month period. There was no a history of preceding patches, erythematous plaques, rash, or pruritic lesions. These lesions were extending over 80% of the skin surface. Histopathologic analysis revealed dense diffuse infiltrates composed of mostly medium-sized to large lymphoid cells throughout the entire dermis without epidermotropism. Neoplastic cells were atypical with markedly pleomorphic nuclei. Immunohistochemistry showed that the tumor cells were positive for CD3, CD4, and CD5 with a loss of CD7. They were negative for CD20, CD8, CD56, CXCL13, PD1, TIA-1, granzyme-B, perforin, CD25, and CD30. The proliferative fraction was low, with MIB-1 labeling less than 10% of cells. The authors diagnosed the patient with primary CPTL-NOS. Despite the rarity of these tumors, clinicians as well as dermatopathologists and pathologists should be familiar with these rare CPTL especially because most of these lymphomas have an aggressive behavior and exhibit an unfavorable prognosis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26262920     DOI: 10.1097/DAD.0000000000000386

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  1 in total

1.  LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.

Authors:  Xiao-Xuan Yu; Meng-Yuan Zhu; Jia-Rong Wang; Hui Li; Po Hu; Ying-Jie Qing; Xiang-Yuan Wang; Hong-Zheng Wang; Zhan-Yu Wang; Jing-Yan Xu; Qing-Long Guo; Hui Hui
Journal:  Acta Pharmacol Sin       Date:  2020-08-03       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.